|
1
|
Azaindoles: noncovalent DprE1 inhibitors from scaffold morphing efforts, kill Mycobacterium tuberculosis and are efficacious in vivo.
|
J Med Chem
|
2013
|
0.97
|
|
2
|
Novel N-linked aminopiperidine-based gyrase inhibitors with improved hERG and in vivo efficacy against Mycobacterium tuberculosis.
|
J Med Chem
|
2014
|
0.93
|
|
3
|
Aminopyrazinamides: novel and specific GyrB inhibitors that kill replicating and nonreplicating Mycobacterium tuberculosis.
|
ACS Chem Biol
|
2012
|
0.90
|
|
4
|
Methyl-thiazoles: a novel mode of inhibition with the potential to develop novel inhibitors targeting InhA in Mycobacterium tuberculosis.
|
J Med Chem
|
2013
|
0.88
|
|
5
|
Optimization of pyrrolamides as mycobacterial GyrB ATPase inhibitors: structure-activity relationship and in vivo efficacy in a mouse model of tuberculosis.
|
Antimicrob Agents Chemother
|
2013
|
0.87
|
|
6
|
4-aminoquinolone piperidine amides: noncovalent inhibitors of DprE1 with long residence time and potent antimycobacterial activity.
|
J Med Chem
|
2014
|
0.82
|
|
7
|
Adenosylcobalamin-dependent glutamate mutase: pre-steady-state kinetic methods for investigating reaction mechanism.
|
Methods Enzymol
|
2002
|
0.79
|
|
8
|
Thiazolopyridine ureas as novel antitubercular agents acting through inhibition of DNA Gyrase B.
|
J Med Chem
|
2013
|
0.78
|